Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 1, 2001, Pages 67-74

  File Jr , T M ^a   Schlemmer, B ^b   Garau, J ^c   Cupo, M ^d   Young, C ^d   Ball, P ^e   Wilson, R ^f,g   Mandell, L ^h   Davies, J ⁱ   Henkel, T ⁱ   McKay, D ⁱ   Aguilar, L ^j   Siquer, B ^k   Hendrick, K ^l  

^a SUMMA HEALTH SYSTEM   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

^d SmithKline Beecham   (United States)

^e UNIVERSITY OF ST ANDREWS   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^l McLaren Family Practice   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G; TROVAFLOXACIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BACTERIUM ISOLATE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INCIDENCE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; NAUSEA; NEUROTOXICITY; PNEUMONIA; POPULATION; RANDOMIZED CONTROLLED TRIAL; RASH; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0034916311     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.1.67     Document Type: Article

References (31)

1. Community-acquired pneumonia
2. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis
3. Community-acquired pneumonia: Epidemiology, etiology, treatment
4. Community-acquired pneumonia in adults: Guidelines for management
5. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
6. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
7. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
8. Trends in the activity of macrolide and β-lactam antibiotics and resistance development
9. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
10. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance Canada, 1997)
11. The role of fluoroquinolones in respiratory tract infections
12. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae
13. FDA Talk Paper: FDA issues public health advisory on liver toxicity associated with the antibiotic Trovan
14. Efficacy and safety of ten-day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia
15. Gatifloxacin
16. Comparative in vitro activity of gemifloxacin
17. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens
18. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
19. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp
20. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae; a review
21. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp
22. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters-Tentative Guideline: Approved Standard M23-T3
23. Pharmacodynamics to combat resistance
24. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection
25. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
26. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in HongKong
27. Fluoroquinolone resistance in Streptococcus pneumoniae
28. Mechanism of fluoroquinolone action
29. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
30. Quinolones and pneumococci